SEC Form 4 · accession 0001012975-19-000225
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Keith Crandell
10% Owner
Robert Nelsen
10% Owner
Clinton Bybee
10% Owner
ARCH Venture Fund VII, L.P.
10% Owner
ARCH Venture Partners VII, LLC
10% Owner
ARCH Venture Partners VII, L.P.
10% Owner
Period of report
Mar 7, 2019
Accepted (ET)
Mar 11, 2019 · 5:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F4,F5 | Mar 7, 2019 | S | 35,209 | $6.8736 | D | 4,601,928 | D | |
| Common StockF2,F4,F5 | Mar 8, 2019 | S | 84,496 | $6.9266 | D | 4,517,432 | D | |
| Common StockF3,F4,F5 | Mar 11, 2019 | S | 44,878 | $6.4924 | D | 4,472,554 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects aggregation of stock sales within the range of $6.66 to $7.00. ARCH Venture Fund VII, L.P. ("ARCH Fund VII") can provide detailed support upon request.
- F2Reflects aggregation of stock sales within the range of $6.50 to $7.17. ARCH Fund VII can provide detailed support upon request.
- F3Reflects aggregation of stock sales within the range of $6.23 to $6.63. ARCH Fund VII can provide detailed support upon request.
- F4Beneficial ownership consists of 4,472,554 shares of common stock held by ARCH Fund VII. The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
- F5The managing directors of ARCH VII LLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by and ARCH Fund VII. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.